Navigation Links
Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
Date:1/29/2009

CHADDS FORD, Pa., Jan. 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that by mutual agreement it has concluded its research collaboration with Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) to develop an inhaled fentanyl product for the treatment of breakthrough pain using Alexza's Staccato(R) inhalation technology. The product, Staccato(R) fentanyl (AZ-003/EN-3284), has completed Phase I clinical testing and will be returned to Alexza. In 2007, Endo licensed exclusive rights to develop and commercialize AZ-003 in North America.

Ivan Gergel, M.D., Endo's executive vice president of research and development, stated: "As a result of our ongoing strategic review initiated last year, we have terminated certain research and development programs. We have enjoyed working with Alexza and wish them success with their drug development programs. In the meantime, we remain committed to building our pipeline by pursuing programs at all phases of development, including potential products arising from our virtual discovery program."

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain i
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will increase to a value of over ... by expansion in the large direct energy device market. ... increasingly adopted due to the advantages they offer and ... findings from Decision Resources Group,s coverage of the U.S. ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana Therapeutics, ... biopharmaceutical company focused on the licensing, development and ... announced positive results from its pivotal field study ... treating pain in dogs with osteoarthritis.  In the ... assessment scores that were statistically significant compared to ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... Development for Chronic Pain and Non-Pain ... Indications -, ... ) today announced that data from its multiple dose clinical,trial of tezampanel, ... the product candidate is safe and,well-tolerated in normal male and female subjects., ...
... Show PTC124 Addresses Underlying Cause of Genetic Disorders and ... Protein Function in Cystic Fibrosis Model, SOUTH PLAINFIELD, N.J., ... new preclinical data in the February 12,2008 edition of the ... PTC124, a novel drug designed to bypass nonsense mutations,was active ...
Cached Medicine Technology:Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 2Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 3Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 4PTC Therapeutics Announces Publication of Preclinical Data in PNAS 2PTC Therapeutics Announces Publication of Preclinical Data in PNAS 3PTC Therapeutics Announces Publication of Preclinical Data in PNAS 4
(Date:12/22/2014)... Carlsbad, Ca (PRWEB) December 22, 2014 ... providing superior senior care service in San ... providing all members of its senior care team ... for caregivers from Golden Care is provided by ... seniors and professional caregivers with the most reliable ...
(Date:12/22/2014)... 22, 2014 Sagacious Consultants, the premier ... subscription option to their ad hoc report writing service ... Customers can sign up for an annual subscription and ... month at a deeply discounted hourly rate. , ... has a progressively discounted rate. Subscription hours are contracted ...
(Date:12/22/2014)... NC (PRWEB) December 22, 2014 ... the current Ebola virus epidemic are receiving ... U.S. government agencies, nongovernmental organizations (NGOs) and ... remains ongoing, healthcare workers, emergency responders, patients ... technologies such as the CmTP MediDefense ...
(Date:12/22/2014)... York, NY (PRWEB) December 22, 2014 ... 2014 stronger than ever, having invested more than ... injured service members, veterans and their families. , ... for nearly a dozen nonprofits, helping with: veteran ... nursing scholarships; and life-coaches for severely injured veterans. ...
(Date:12/22/2014)... 22, 2014 Give a loved one ... gift of health and vitality. , For a limited ... top-selling anti-aging formulas in special Holiday Wellness gift packages ... , Each bottle contains cutting-edge, proven nutritional support ... work as well as we age. , ...
Breaking Medicine News(10 mins):Health News:Golden Care Partners with Nationally Recognized Caregiver Training Service 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2
... , , SOLON, Ohio, Aug. ... U.S. marketplace, Nestle USA is pleased to announce that NESTLE TOLL ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090818/SF63053-a ) , (Photo: http://www.newscom.com/cgi-bin/prnh/20090818/SF63053-b ) ... retail partners and consumers to identify the new batch of cookie ...
... home foreclosure epidemic may be taking its toll on ... of people studied while undergoing foreclosure reported depressive symptoms, ... according to new University of Pennsylvania School of Medicine ... Journal of Public Health. Many also reported an ...
... in the normal range appear to be associated with ... new study published online August 21 in the ... growth factors appear to be involved in the development ... levels and prostate cancer risk has been unclear. ...
... ... control a cell,s ability to adapt to changes in its environment, a finding that could ... , ... August 21, 2009 -- UCSF researchers have identified the two key circuits that control a ...
... , DALLAS, Aug. 21 Michael Ramsay, ... chief of the department of anesthesiology and pain management ... elected president of the International Liver Transplant Society (ILTS), ... international members specializing in hepatology, surgery, anesthesia, critical care, ...
... , , , , ... America, Inc., a leader in the home and office bottled water, filtration ... a three-year alliance with Susan G. Komen for the Cure(R), the world,s ... office bottled water brands, DS Waters will make a $30.00 donation to ...
Cached Medicine News:Health News:Updated With Photos: NESTLE(R) TOLL HOUSE(R) Re-launches With 'New Batch' Label 2Health News:More than 1/3 of homeowners in foreclosure suffer from major depression, Penn study shows 2Health News:More than 1/3 of homeowners in foreclosure suffer from major depression, Penn study shows 3Health News:UCSF Researchers Identify Two Key Pathways in Adaptive Response 2Health News:UCSF Researchers Identify Two Key Pathways in Adaptive Response 3Health News:UCSF Researchers Identify Two Key Pathways in Adaptive Response 4Health News:Dallas Physician Elected to Lead International Organ Transplant Society 2Health News:Dallas Physician Elected to Lead International Organ Transplant Society 3Health News:DS Waters of America, Inc. Partners With Susan G. Komen for the Cure(R) 2Health News:DS Waters of America, Inc. Partners With Susan G. Komen for the Cure(R) 3Health News:DS Waters of America, Inc. Partners With Susan G. Komen for the Cure(R) 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: